Top

Published in:

01-12-2009 | Original Article

Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort

Authors: Stina Syrjänen, Paulo Naud, Luis Sarian, Sophie Derchain, Cecilia Roteli-Martins, Adhemar Longatto-Filho, Silvio Tatti, Margherita Branca, Mojca Eržen, L. S. Hammes, S. Costa, Kari Syrjänen

Published in: Virchows Archiv | Issue 6/2009

Abstract

Bypassing the local immunological defense reactions in the cervix is one of the prerequisites for human papillomaviruses (HPV) infections to progress to intraepithelial neoplasia (CIN). The role of potent immunosuppressive cytokines, e.g., interleukin-10 (IL-10), depressing these local virus-specific immunological responses is incompletely studied. To assess, whether IL-10 expression in cervical HPV lesions has any implications in the outcome of HPV infections or disease progression to CIN. Baseline cervical biopsies from 225 women of the LAMS study sub-cohort were analyzed for IL-10 expression using immunohistochemistry, to assess its associations with CIN grade, and high-risk HPV (HR-HPV) at baseline, as well as in predicting outcomes of HR-HPV infections, and development of incident CIN1+ and CIN2+ in this longitudinal setting. Expression of IL-10 in cervical lesions was up-regulated most often in high-grade CIN, and IL-10 over-expression retained its value as independent predictor of CIN2+ (odds ratio (OR) = 4.92) and CIN3+ (OR = 7.51) also in multivariate model, including HR-HPV and several known covariates of IL-10 expression. Up-regulation was not related to HR-HPV detection, and showed no relationship to HR-HPV viral loads. Using longitudinal predictive indicators (SE, SP, PPV, NPV), IL-10 expression was of no value in predicting (1) the outcomes of HR-HPV infections, or (2) the surrogate endpoints (incident CIN1+, CIN2+) of progressive disease. IL-10 over-expression (along with HR-HPV) was one of the independent covariates of CIN2/3. This immunosuppressive cytokine might play an important role in creating a microenvironment that favors progressive cervical disease and immune evasion by HR-HPV.

zur Hausen H (2009) Papillomaviruses in the causation of human cancers—a brief historical account. Virology 384:260–265CrossRefPubMed

Syrjänen KJ (1987) Biology of human papillomavirus (HPV) infections and their role in squamous cell carcinogenesis. Med Biol 65:21–39PubMed

Syrjänen K, Syrjänen S (2000) Papillomavirus infections in human pathology. Wiley, New York, pp 1–615

Syrjänen S, Syrjänen K (2008) The history of papillomavirus research. Cent Eur J Public Health 16(Suppl):S7–13PubMed

Munoz N, Bosch FX, de Sanjose S et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527CrossRefPubMed

Cliffort GM, Gallus S, Herrero R et al (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for research on Cancer HPV prevalence surveys: pooled analysis. Lancet 366:991–998CrossRef

Syrjänen SM, Syrjänen KJ (1999) New concepts on the role of human papillomavirus in cell cycle regulation. Ann Med 31:175–187CrossRefPubMed

von Knebel Doeberitz M (2002) New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 38:2229–2242CrossRef

Munger K, Baldwin A, Edwards KM et al (2004) Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78:11451–11460CrossRefPubMed

10.

Branca M, Ciotti M, Santini D et al (2004) p16^INK4A expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 23:354–365CrossRefPubMed

11.

Santopietro R, Shabalova IP, Petrovichev N et al (2006) Cell cycle regulators p105, p107, Rb2/p130, E2F4, p21^CIP1/WAF1, cyclin-A in predicting CIN, high-risk human papillomavirus infections and their outcome in women screened in three New Independent States of the Former Soviet Union. Cancer Epidemiol Biomark Prev 15:1250–1256CrossRef

12.

Stanley M (2006) Immune responses to human papillomavirus. Vaccine 24S:16–22CrossRef

13.

Syrjänen K (2000) Immunology of HPV infections and prospects for vaccination. Chapter 21. In: Syrjänen K, Syrjänen S (eds) Papillomavirus infections in human pathology. Wiley, New York, pp 459–490

14.

Moore KW, de Waal MR, Coffman RL et al (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765CrossRefPubMed

15.

Mosser DM, Zhang X (2008) Interleukin-10: new perspectives on an old cytokine. Immunol Rev 226:205–218CrossRefPubMed

16.

Fiorentino DF, Bond MW, Mosmann TR (1989) Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170:2081–2095CrossRefPubMed

17.

Alcocer-Gonzalez JM, Berumen J, Tamez-Guerra R et al (2006) In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol 19:481–491CrossRefPubMed

18.

de Waal Malefyt R, Haanen J, Spits HM et al (1991) Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen specific human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression. J Exp Med 174:915–920CrossRefPubMed

19.

Clerici M, Merola M, Ferrario E et al (1997) Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 89:245–50CrossRefPubMed

20.

de Gruijl TD, Bontkes HJ, van den Muysenberg AJ et al (1999) Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. Eur J Cancer 35:490–497CrossRefPubMed

21.

Santin AD, Hermonat PL, Ravaggi A et al (2000) Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol 74:4729–4737CrossRefPubMed

22.

Kobayashi A, Greenblatt RM, Anastos K et al (2004) Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 64:6766–6774CrossRefPubMed

23.

Syrjänen K, Naud P, Derchain SM et al (2005) Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study. Anticancer Res 25:3469–3480PubMed

24.

Longatto-Filho A, Maeda MYS, Eržen M et al (2005) Conventional PAP smear and liquid-based cytology as screening tools in low-resource settings of Latin America. Experience of the Latin American Screening Study. Acta Cytol 49:500–506PubMed

25.

Sarian L, Derchain SM, Naud P et al (2005) Evaluation of visual inspection with acetic acid (VIA), Lugol’s iodine (VILI) cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin American Screening) study. J Med Screen 12:142–149CrossRefPubMed

26.

Longatto-Filho A, Eržen M, Branca M et al (2006) Human papillomavirus (HPV) testing as an optional screening tool in low-resource settings of Latin America. Experience from the LAMS study. Int J Gynecol Cancer 16:955–962CrossRefPubMed

27.

Syrjänen K, Shabalova I, Naud P et al (2009) Persistent high-risk human papillomavirus (HPV) infections and other endpoint markers of progressive cervical disease among women prospectively followed-up in the NIS and LAMS cohorts. Int J Gynecol Cancer 19:934–942PubMed

28.

Seed PT, Tobias A (2001) Summary statistics for diagnostic tests. Stata Techn Bull 59:9–12

29.

Syrjänen KJ (1983) Immunocompetent cells in uterine cervical lesions of human papillomavirus (HPV) origin. Gynecol Obstet Invest 16:327–340PubMedCrossRef

30.

Väyrynen M, Syrjänen K, Mäntyjärvi R et al (1985) Immunophenotypes of lymphocytes in prospectively followed up human papillomavirus lesions of the cervix. Genitourin Med 61:190–196PubMed

31.

Väyrynen M, Syrjänen K, Mäntyjärvi R et al (1984) Langerhans cells in human papillomavirus (HPV) lesions of the uterine cervix identified by the monoclonal antibody OKT-6. Int J Gynaecol Obstet 22:375–383CrossRefPubMed

32.

Syrjänen K, Väyrynen M, Mäntyjärvi R et al (1986) Natural killer (NK) cells with HNK-1 phenotype in the cervical biopsies of women followed-up for human papillomavirus (HPV) lesions. Acta Obstet Gynecol Scand 65:139–145PubMedCrossRef

33.

Syrjänen K, Väyrynen M, Castren O et al (1984) The relation between the type of immunoreactive cells found in human papillomavirus (HPV) lesions of the uterine cervix and the subsequent behaviour of these lesions. Arch Gynecol 234:189–196CrossRefPubMed

34.

Syrjänen K, Väyrynen M, Hippeläinen M et al (1985) The in situ immunological reactivity and its significance in the clinical behaviour of the cervical human papillomavirus lesions. Neoplasma 32:181–190PubMed

35.

Williams LM, Ricchetti G, Sarma U et al (2004) Interleukin-10 suppression of myeloid cell activation—a continuing puzzle. Immunology 113:281–292CrossRefPubMed

36.

Mindiola R, Caulejas D, Nunez-Troconis J et al (2008) Increased number of IL-2, IL-2 receptor and IL-10 positive cells in premalignant lesions of the cervix. Invest Clin 49:533–545PubMed

37.

Giannini SL, Al-Saleh W, Piron H et al (1998) Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin Exp Immunol 113:183–189CrossRefPubMed

38.

Scott ME, Ma Y, Kuzmich L, Moscicki AB (2009) Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3. Int J Cancer 124:1379–1383CrossRefPubMed

39.

Branca M, Ciotti M, Giorgi C et al (2008) Predicting high-risk human papillomavirus (HPV) infection, progression of cervical intraepithelial neoplasia (CIN) and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modelling. Int J Gynecol Pathol 27:265–273PubMed

Title: Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort
Authors: Stina Syrjänen
Paulo Naud
Luis Sarian
Sophie Derchain
Cecilia Roteli-Martins
Adhemar Longatto-Filho
Silvio Tatti
Margherita Branca
Mojca Eržen
L. S. Hammes
S. Costa
Kari Syrjänen
Publication date: 01-12-2009
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 6/2009
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-009-0850-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2009

Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue

Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2

Encapsulated apocrine papillary carcinoma of the breast—a tumour of uncertain malignant potential: report of five cases

Borderline and malignant phyllodes tumors display similar promoter methylation profiles

Colonic carcinoma with a pancreatic acinar cell differentiation. A case report

Expression of MMP-10, MMP-21, MMP-26, and MMP-28 in Merkel cell carcinoma